Setback for Sepracor

The drug developer's shares are suffering after the drug it licensed to Schering-Plough encountered FDA delays. Also: opinions on JDS Uniphase and PMC-Sierra, plus others

Sepracor (SEPR ) Downgrades from 4 STARS (accumulate) to 3 STARS (hold)

To continue reading this article you must be a Bloomberg Professional Service Subscriber.